One Of The Five Cyclos Is Five-membered And Includes Ring Chalcogen (e.g., Codeine, Morphine, Etc.) Patents (Class 514/282)
  • Patent number: 11986472
    Abstract: The present disclosure is directed to a method of combatting opioid dependence in a subject who is misusing alcohol or susceptible to alcohol misuse. The method comprises treating the subject with an opioid agonist whilst managing their alcohol consumption using a step-wise interactive process, particularly where the process involves virtual cognitive behavioral therapy comprising a program for self-treatment. The self-treatment program could be embodied as a mobile medical application.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: May 21, 2024
    Assignee: OREXO AB
    Inventor: Michael John Sumner
  • Patent number: 11975096
    Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.
    Type: Grant
    Filed: August 25, 2021
    Date of Patent: May 7, 2024
    Assignee: Hikma Pharmaceuticals USA Inc.
    Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
  • Patent number: 11969413
    Abstract: This present invention relates to pharmaceutical composition comprising Deutetrabenazine. The invention also relates to the methods of preparation of the composition having improved stability and dissolution profile and used for the treatment of chorea associated with Huntington disease and tardive dyskinesia.
    Type: Grant
    Filed: October 26, 2021
    Date of Patent: April 30, 2024
    Assignee: Aurobindo Pharma Ltd
    Inventors: Saravanan Kannusamy, Prabhakaran Chakkirala, Nagaprasad Vishnubhotla, Sivakumaran Meenakshisunderam
  • Patent number: 11957676
    Abstract: A controlled release formulation comprising an opioid growth factor receptor (OGFR) antagonist and at least one pharmaceutically acceptable carrier has been developed, which is useful for treating cancer when locally administered at a disease site.
    Type: Grant
    Filed: August 7, 2023
    Date of Patent: April 16, 2024
    Assignee: Zetagen Therapeutics, Inc.
    Inventor: Bryan S. Margulies
  • Patent number: 11938224
    Abstract: A 12-hour anti-tussive modified release solid tablet or tablet-in-capsule is described which comprises a benzonatate-silicon dioxide adsorbate powder in a hydrophilic matrix to provide a 12-hour modified release profile to the benzonatate, wherein there is substantially no benzonatate release from the tablet or capsule in the buccal cavity and no more than about 1% release of the benzonatate within half an hour as determined in an in vitro dissolution assay.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: March 26, 2024
    Assignee: TRIS PHARMA INC
    Inventors: Andrea Nelson, Sachin Chaudhari, Nemichand B. Jain, Shivanand Puthli
  • Patent number: 11925635
    Abstract: The present invention provides methods for treating and/or managing pain. The invention further provides methods for reducing or inhibiting opioid tolerance, reducing risk of opioid addiction or dependence, restoring opioid efficacy, and enhancing the therapeutic effect of an opioid. The invention further provides compositions for use in the methods of the invention.
    Type: Grant
    Filed: December 20, 2021
    Date of Patent: March 12, 2024
    Assignee: East Carolina University
    Inventors: Kori Brewer, Stefan Clemens
  • Patent number: 11918655
    Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.
    Type: Grant
    Filed: June 7, 2023
    Date of Patent: March 5, 2024
    Assignee: AEGIS THERAPEUTICS, LLC
    Inventors: Richard Lowenthal, Edward T. Maggio, Robert G. Bell, Pratik Shah
  • Patent number: 11883392
    Abstract: According to the invention, there is provided a solid pharmaceutical composition formulation for nasal delivery of an opioid antagonist, comprising a pharmacologically-effective amount of an opioid antagonist and a pharmaceutically-acceptable carrier. The compositions are preferably in the form of a powder produced by spray-drying, which are subsequently loaded into single use nasal applicators. Preferred pharmaceutically-acceptable carriers in this regard include disaccharides (e.g. lactose or trehalose) and dextrins (e.g. cyclodextrins or maltodextrins), preferably spray-dried together in combination. Compositions may further comprise an alkyl saccharide, preferably a sucrose ester, such as sucrose monolaurate. The compositions and applicators may be employed in the treatment of opioid overdose in subjects.
    Type: Grant
    Filed: February 10, 2021
    Date of Patent: January 30, 2024
    Assignee: OREXO AB
    Inventors: Jonas Sävmarker, Robert Rönn, Andreas Fischer
  • Patent number: 11865112
    Abstract: Disclosed in certain embodiments is a pharmaceutical formulation (e.g., parenteral formulation) comprising a therapeutically effective amount of nalmefene or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable adjuvant (e.g., parenterally acceptable adjuvant) that promotes the rate at which the nalmefene or salt thereof is more rapidly absorbed into the systemic circulation of a subject identified as in need thereof.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: January 9, 2024
    Assignee: Purdue Pharma L.P.
    Inventors: Haiyong Hugh Huang, Manjunath S. Shet
  • Patent number: 11752110
    Abstract: Transdermal therapeutic system for the transdermal administration of a systemically active agent comprising a self-adhesive layer structure, comprising A) a backing layer, and B) a dried biphasic layer, the dried biphasic layer having a) an outer phase having a composition comprising 75% to 100% of a polymer or polymer mixture, and b) an inner phase having a composition comprising at least one active agent, wherein the inner phase forms dispersed deposits in the outer phase, and c) 0.1% to 3.5% of an interface mediator with a kinematic viscosity of from 10 cSt to 100 000 cSt at 25° C., and C) optionally an additional skin contact layer.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: September 12, 2023
    Assignee: LTS Lohmann Therapie-Systeme AG
    Inventors: Marco Emgenbroich, Johannes Josef Leonhard, Kristina Kassner, Aurélia Lappert
  • Patent number: 11752143
    Abstract: Methods of using low dose naltrexone to treat chronic pain in a patient. The methods of using low dose naltrexone to treat chronic pain generally includes administering to the patient a first amount of naltrexone in an immediate-release agent and a second amount of naltrexone in a modified-release agent.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: September 12, 2023
    Assignee: Soin Therapeutics LLC
    Inventor: Amol N. Soin
  • Patent number: 11744895
    Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.
    Type: Grant
    Filed: August 6, 2021
    Date of Patent: September 5, 2023
    Assignee: AEGIS THERAPEUTICS, LLC
    Inventors: Richard Lowenthal, Edward T. Maggio, Robert G. Bell, Pratik Shah
  • Patent number: 11717571
    Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.
    Type: Grant
    Filed: October 26, 2022
    Date of Patent: August 8, 2023
    Assignee: AEGIS THERAPEUTICS, LLC
    Inventors: Richard Lowenthal, Edward T. Maggio, Robert G. Bell, Pratik Shah
  • Patent number: 11642341
    Abstract: A medicament comprising (I) brexpiprazole or a pharmaceutically acceptable salt thereof, and (II) nalmefene or a pharmaceutically acceptable salt thereof in combination, wherein brexpiprazole or a pharmaceutically acceptable salt thereof, and nalmefene or a pharmaceutically acceptable salt thereof are contained in a single preparation, or a pharmaceutical composition containing brexpiprazole or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing nalmefene or a pharmaceutically acceptable salt thereof are formulated for use in combination. The medicament is used for the prophylaxis or treatment of a substance-related disorder, preferably an alcohol-related disorder.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: May 9, 2023
    Assignees: Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S
    Inventors: Kenji Maeda, Mai Nakamura
  • Patent number: 11628139
    Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: April 18, 2023
    Assignee: Hikma Pharmaceuticals USA Inc.
    Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
  • Patent number: 11617713
    Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: April 4, 2023
    Assignee: Hikma Pharmaceuticals USA Inc.
    Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
  • Patent number: 11613547
    Abstract: In some aspects, the present disclosure provides compounds of the formula: wherein the variables are as defined herein. In some embodiments, these compounds may be used to reduce the pain of a patient. These compounds may be used in pain relief and show an improved pharmaceutical profile relative to other commonly used opiates and opioid derivatives.
    Type: Grant
    Filed: July 8, 2020
    Date of Patent: March 28, 2023
    Assignees: University of Health Sciences & Pharmacy in St. Louis, University of Southern California, The University of North Carolina at Chapel Hill, Memorial Sloan Kettering Cancer Center, University of Florida Research Foundation, Incorporated
    Inventors: Susruta Majumdar, Vsevolod Katritch, Bryan Roth, Jay McLaughlin, Saheem Zaidi, Gavril W. Pasternak, Rajendra Uprety
  • Patent number: 11534409
    Abstract: Described are immediate release oral dosage forms that contain abuse-deterrent features. In particular, the disclosed dosage forms provide deterrence of abuse by ingestion of multiple individual doses. In addition, the disclosed dosage forms provide protection from overdose in the event of accidental or intentional ingestion of multiple individual doses.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: December 27, 2022
    Assignee: Clexio Biosciences Ltd.
    Inventors: Dinesh K. Haswani, Derek V. Moe, Victoria A. O'Neill, Randal A. Seburg, Manuel A. Vega Zepeda
  • Patent number: 11517524
    Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: December 6, 2022
    Assignees: BioXcel Therapeutics, Inc., ARx, LLC
    Inventors: Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
  • Patent number: 11505556
    Abstract: The present invention encompasses improved morphian compositions and methods of use of the improved compositions for modulating neuropathic pain, opioid-induced glial activation, or a combination thereof beyond what is currently known in the art. The methods involve administering the compound of Formula I to a subject.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: November 22, 2022
    Assignee: Xalud Therapeutics, Inc.
    Inventors: Raymond A. Chavez, Stephen Collins
  • Patent number: 11497711
    Abstract: Disclosed herein is a self-supporting, dissolvable, film containing dexmedetomidine or a pharmaceutically acceptable salt thereof. The film is administered orally to treat various conditions, particularly agitation, by transmucosal delivery of the active agent.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: November 15, 2022
    Assignees: BioXcel Therapeutics, Inc., ARx, LLC
    Inventors: Vasukumar Kakumanu, David Christian Hanley, Frank Yocca, Chetan Dalpatbhai Lathia, Scott David Barnhart
  • Patent number: 11464772
    Abstract: The invention provides methods for treating chronic and acute pain. For example, the invention provides methods of treating neuropathic and inflammatory pain.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: October 11, 2022
    Assignee: Blue Therapeutics, Inc.
    Inventors: Ajay Yekkirala, David Roberson, Michio Painter
  • Patent number: 11446293
    Abstract: Extended release, abuse deterrent dosage forms comprising crush-resistant controlled-release particles that provide abuse deterrent properties to the dosage forms. The crush-resistant controlled-release particles, which comprise plastic/elastic polymers and at least one active pharmaceutical ingredient (API) or a pharmaceutically acceptable salt thereof, are prepared by a hot melt extrusion process.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: September 20, 2022
    Assignee: SpecGX LLC
    Inventors: Jonathan Gaik, Jaehan Park, Ryan Lathrop, Gary Nichols, John Schallom
  • Patent number: 11433063
    Abstract: Nasally targeted dry powder compositions and methods for their use in the treatment of exposure to organophosphate compounds including chemical warfare agents and pesticides. Compositions include anticholinergic agents and cholinesterase reactivator agents used for primary treatment and vasoactive agents and benzodiazepines used for secondary treatment of exposure, and combinations of these agents. Compositions incorporate excipients and enabling agents such as permeation enhancers, and optimal sizing of active pharmaceutical ingredient particle size to improve drug delivery across the nasal mucosa, stability, and resistance to heat degradation. Packaging and configuration of devices for dry powder nasal compositions enable their use by non-medical personnel in civilian mass casualty or battlefield environments.
    Type: Grant
    Filed: March 4, 2022
    Date of Patent: September 6, 2022
    Assignee: BELHAVEN BIOPHARMA, INC.
    Inventors: Barry Bleske, Ted William Lanpher
  • Patent number: 11369579
    Abstract: The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 5.9, 30.2, and 31.2 degrees; or a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 3.7, 5.9, and 26.6 degrees. The present disclosure provides polymorphic forms of sodium benzoate with a X-ray diffraction pattern comprising characteristic peaks at a reflection angle 2? of approximately 3.6, 7.5, 26.6, and 29.4 degrees. Also provided herein are methods of preparing the polymorphic forms of sodium benzoate and uses thereof in treating and/or reducing the risk for a neuropsychiatric disorder (e.g., schizophrenia, psychotic disorders, depressive disorders, or Alzheimer's disease).
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: June 28, 2022
    Assignee: SyneuRx International (Taiwan) Corp.
    Inventors: Guochuan Emil Tsai, Ching-Cheng Wang, Tien-Lan Hsieh
  • Patent number: 11351165
    Abstract: It has been found by the present inventors that agents that boost the expression of the opioid receptor kappa 1 (OPRK1) can enhance the cytotoxicity of chemotherapeutic agents in multiple cancer cell lines. Furthermore, the effect is dose dependent, where the greater the induced expression of OPRK1, the greater the cytotoxicity of the chemotherapeutic agent. The increase in overall cytotoxicity is independent of the cytotoxicity of the agent that increases the expression of OPRK1, which itself has no or minimal cytotoxic effect.
    Type: Grant
    Filed: March 28, 2018
    Date of Patent: June 7, 2022
    Assignee: LDN Pharma Limited
    Inventors: Angus Dalgleish, Wai Lui
  • Patent number: 11311532
    Abstract: Solid pharmaceutical compositions with high drug loading are provided. A formulation useful for the solid pharmaceutical composition includes valbenazine, or a pharmaceutically acceptable salt thereof, silicified microcrystalline cellulose, isomalt, hydroxypropyl methylcellulose, partially pregelatinized maize starch, and magnesium stearate.
    Type: Grant
    Filed: October 19, 2020
    Date of Patent: April 26, 2022
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Richard Alexander Moore, Jr., Gregory A. McClelland, Christopher F. O'Brien
  • Patent number: 11278544
    Abstract: Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is an opioid antagonist and the second compound causes increased agonism of a melanocortin 3 receptor (MC3-R) or a melanocortin 4 receptor (MC4-R) compared to normal physiological conditions. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual to antagonize opioid receptor activity and to enhance ?-MSH activity.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: March 22, 2022
    Assignee: Nalpropion Pharmaceuticals LLC
    Inventors: Eckard Weber, Michael Alexander Cowley
  • Patent number: 11273133
    Abstract: Dosage forms, drug delivery systems, methods related to sustained release of dextromethorphan or improved therapeutic effects. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: March 15, 2022
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 11234946
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: February 1, 2022
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 11214577
    Abstract: The present invention related to novel morphinans, compositions comprising the novel morphinans, and their uses as agonists of the kappa opioid receptor.
    Type: Grant
    Filed: March 30, 2020
    Date of Patent: January 4, 2022
    Assignee: Humanwell Pharmaceutical US
    Inventors: Subo Liao, Jun Yang, Jie Li, Wentao Du, Lie Li, Jinliang Lv, Zongquan Liao, Hao Zhou, Tianpeng Xie, Jianbo Yu
  • Patent number: 11207281
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: December 28, 2021
    Assignee: ANTECIP BIOVENTURES II LLC
    Inventor: Herriot Tabuteau
  • Patent number: 11207317
    Abstract: Methylnaltrexone nasal formulations are disclosed which provide improved bioavailability over oral dosage forms and improved patient compliance over injectable dosage forms. Also disclosed are methods of making the nasal formulations and methods of using, specifically to treat the side effects of opioid drug use, such as constipation, and other indications.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: December 28, 2021
    Assignee: APTAPHARMA INC.
    Inventor: Siva Rama K. Nutalapati
  • Patent number: 11202777
    Abstract: The present invention provides methods for treating and/or managing pain. The invention further provides methods for reducing or inhibiting opioid tolerance, reducing risk of opioid addiction or dependence, restoring opioid efficacy, and enhancing the therapeutic effect of an opioid. The invention further provides compositions for use in the methods of the invention.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: December 21, 2021
    Assignee: East Carolina University
    Inventors: Kori Brewer, Stefan Clemens
  • Patent number: 11191838
    Abstract: Drug products adapted for nasal delivery comprising formulations with epinephrine and devices comprising such formulations are provided. Methods of treating anaphylaxis with epinephrine products are also provided.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: December 7, 2021
    Assignee: AEGIS THERAPEUTICS, LLC
    Inventors: Richard Lowenthal, Edward T. Maggio, Robert G. Bell, Pratik Shah
  • Patent number: 11185509
    Abstract: A solid preparation includes a 4,5-epoxymorphinan derivative or a pharmaceutically acceptable acid addition salt thereof, which is stable to light even without light shielding coating. The solid preparation includes an active ingredient composed of a 4,5-epoxymorphinan derivative or a pharmaceutically acceptable acid addition salt thereof, and one or more stabilizing agents selected from the group consisting of n-propyl gallate, sodium hydrogensulfite, dibutylhydroxytoluene, butylhydroxyanisole, tocopherol and D-isoascorbic acid, wherein the amount of the above active ingredient is 0.00001 to 0.01% by weight of the solid preparation, and the amount of the above stabilizing agent is 0.005 to 5% by weight of the solid preparation.
    Type: Grant
    Filed: July 28, 2017
    Date of Patent: November 30, 2021
    Assignee: Toray Industries, Inc.
    Inventors: Suguru Takaki, Satoshi Minakami, Kotoe Ohta
  • Patent number: 11185540
    Abstract: Pharmaceutical compositions of one or more opioid antagonists or phosphodiesterase 5 (PDE5) inhibitors are disclosed.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: November 30, 2021
    Assignee: PARDON MY SCOTCH LLC.
    Inventor: Michael Anthony Pavlovich
  • Patent number: 11173209
    Abstract: The present invention provides compositions and methods and for increasing the bioavailability of therapeutic agents in a subject. The compositions include at least one alkyl glycoside and at least one therapeutic agent, wherein the alkylglycoside has an alkyl chain length from about 10 to about 16 carbon atoms.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: November 16, 2021
    Assignee: AEGIS THERAPEUTICS, LLC
    Inventor: Edward T. Maggio
  • Patent number: 11139056
    Abstract: The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.
    Type: Grant
    Filed: September 2, 2019
    Date of Patent: October 5, 2021
    Assignee: Nalpropion Pharmaceuticals LLC
    Inventors: Preston Klassen, Kristin Taylor
  • Patent number: 11129826
    Abstract: Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: September 28, 2021
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Patent number: 11103581
    Abstract: An abuse deterrent pharmaceutical composition including an acid soluble salt of a pharmaceutically active ingredient and a buffering ingredient; wherein the acid soluble salt of the pharmaceutically active ingredient and the buffering ingredient retard release of the pharmaceutically active ingredient when the composition is ingested in excess of an intended dosage.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: August 31, 2021
    Assignee: Acura Pharmaceuticals, Inc.
    Inventor: Robert Barnett Jones
  • Patent number: 11083794
    Abstract: An abuse deterrent pharmaceutical composition including a pharmaceutically active ingredient; an acid soluble ingredient; and a buffering ingredient; wherein the acid soluble ingredient and the buffering ingredient retard release of the active pharmaceutical ingredient when the composition is ingested in excess of an intended dosage.
    Type: Grant
    Filed: June 11, 2020
    Date of Patent: August 10, 2021
    Assignee: Acura Pharmaceuticals, Inc.
    Inventors: Albert W. Brzeczko, R. Gary Hollenbeck
  • Patent number: 11071734
    Abstract: A tableted pharmaceutical composition contains nalfurafine or a pharmaceutically acceptable acid addition salt thereof and is excellent in formability and quality control of related substances. The tableted pharmaceutical composition includes nalfurafine or a pharmaceutically acceptable acid addition salt thereof, a binder component, and a carrier, wherein the above mentioned nalfurafine or a pharmaceutically acceptable acid addition salt thereof is contained in an amount of 0.1 to 10 ?g, and the weight of the above mentioned binder component is 100,000 to 2,000,000 weight % based on the weight of the above mentioned nalfurafine or a pharmaceutically acceptable acid addition salt thereof and 5 to 20 weight % based on the total weight of the resulting pharmaceutical composition, or 20,000 to 500,000 weight % and 1 to 5 weight % based on the total weight of the resulting pharmaceutical composition.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: July 27, 2021
    Assignee: Toray Industries, Inc.
    Inventors: Satoshi Minakami, Suguru Takaki, Kotoe Ohta, Yasuhide Horiuchi
  • Patent number: 11045478
    Abstract: Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: June 29, 2021
    Assignee: ESSENTIALIS, INC.
    Inventors: Neil M. Cowen, Khaled A. Yamout
  • Patent number: 11026939
    Abstract: Solid pharmaceutical compositions with high drug loading are provided. A formulation useful for the solid pharmaceutical composition includes valbenazine, or a pharmaceutically acceptable salt thereof, silicified microcrystalline cellulose, isomalt, hydroxypropyl methylcellulose, partially pregelatinized maize starch, and magnesium stearate.
    Type: Grant
    Filed: October 19, 2020
    Date of Patent: June 8, 2021
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Richard Alexander Moore, Jr., Gregory A. McClelland, Christopher F. O{grave over ( )}Brien
  • Patent number: 11014933
    Abstract: Non-peptide MOR opioid receptor modulators are provided. The compounds exhibit predominantly central activity and are used to treat e.g. substance use disorders, and pain.
    Type: Grant
    Filed: December 24, 2019
    Date of Patent: May 25, 2021
    Assignee: VIRGINIA COMMONWEALTH UNIVERSITY
    Inventor: Yan Zhang
  • Patent number: 10988481
    Abstract: Analogues of 6 ?/?-naltrexamine (NAQ) are provided. The analogues are selective, reversible antagonists of the mu opioid receptor (MOR) that exhibit good blood brain barrier penetration. The compounds are used in the treatment of opioid addiction and other diseases and conditions, including for the treatment of pain.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: April 27, 2021
    Assignee: Virginia Commonwealth University
    Inventors: Yan Zhang, Dana E. Selley, William Dewey, Hamid Abkarali
  • Patent number: 10987350
    Abstract: Disclosed and described is a novel dose titration procedure for administering the opioid antagonist, nalmefene, to a patient diagnosed with post-traumatic stress disorder (PTSD).
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: April 27, 2021
    Inventors: Hillel Glover, Lillian Hahn
  • Patent number: 10973814
    Abstract: The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: April 13, 2021
    Assignee: HIKMA PHARMACEUTICALS USA INC.
    Inventors: Kiran Amancha, Chandeshwari Chilampalli, Thrimoorthy Potta, Ningxin Yan, Venkat R. Goskonda
  • Patent number: 10967065
    Abstract: In some aspects, pegylated aminoglycoside compounds are provided. In some embodiments, m-PEG-tobramycin compounds may be used to treat a biofilm infection or reduce or treat established biofilms.
    Type: Grant
    Filed: April 30, 2019
    Date of Patent: April 6, 2021
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Hugh Smyth, Ju Du